COPENHAGEN, DENMARK — July 19, 2002 —
Recombinant human erythropoietin once weekly is an effective and safe treatment for anaemia in haemodialysis patients.
Investigators led by Dr. Paul Barre from the Royal Victoria Hospital, Montreal, Quebec, Canada, conducted an international, multicentre study to clarify whether haemodialysis patients could maintain haemoglobin levels after switching from two- or three-times weekly dosing to once-weekly recombinant human erythropoietin.
They reported the findings here July 15 at the 39th annual Congress of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA). The 20-week study enrolled 358 haemodialysis patients (173 intravenous and 185 subcutaneous) who were on haemodialysis for more than one year, were receiving epoetin for more than six
months, and had adequate iron stores (greater than 100 µg/L, TSAT20 percent or greater).
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!